Results 31 to 40 of about 10,632 (179)

Conformational asymmetry of human immunodeficiency virus‐1 protease flaps increases along the darunavir drug resistance pathway

Protein Science, Volume 35, Issue 9, September 2026.
Abstract Under selective drug pressure, the structure and dynamics of HIV‐1 protease (PR) evolve to confer resistance to the drug. Here, we report on the conformational changes in PR flaps for drug‐resistance mutations using 19F nuclear magnetic resonance (NMR) spectroscopy.
Michel Guerrero, Roman Zadorozhnyi, Guowu Lin, Caitlin M. Quinn, Guillermo Calero, Nese Kurt‐Yilmaz, Celia A. Schiffer, Tatyana Polenova, Angela M. Gronenborn, Rieko Ishima   +9 more
wiley   +1 more source

Combating HIV resistance – focus on darunavir

Therapeutics and Clinical Risk Management, 2008
Cécile L Tremblay11Department of Microbiology and Immunology, Centre Hospitalier de l’Université de Montréal, Montréal, CanadaAbstract: Darunavir is a second-generation protease inhibitor designed to ...
Cécile L Tremblay
doaj  

Virologic response to tipranavir-ritonavir or darunavir-ritonavir based regimens in antiretroviral therapy experienced HIV-1 patients: a meta-analysis and meta-regression of randomized controlled clinical trials. [PDF]

PLoS ONE, 2013
The development of tipranavir and darunavir, second generation non-peptidic HIV protease inhibitors, with marked improved resistance profiles, has opened a new perspective on the treatment of antiretroviral therapy (ART) experienced HIV patients with ...
Asres Berhan, Yifru Berhan
doaj   +1 more source

SARS‐CoV‐2 mRNA Vaccination Induces Neutralizing Antibodies and Type I IFN Changes in People Living With HIV

Journal of Medical Virology, Volume 98, Issue 8, August 2026.
ABSTRACT This study examined changes in anti‐Spike (anti‐S) antibodies (Abs) and type I interferon (IFN‐I) following the BNT162b2 vaccine in people living with HIV (PLWH) and analyzed the impact of demographic and immunological factors. In total, 75 PLWH and 28 healthy donors were followed at baseline (T0), at the second dose (T1), after the second ...
Federica Frasca, Luca Maddaloni, Alessandra D'Auria, Matteo Fracella, Ginevra Bugani, Carmen Falvino, Valentina Baccolini, Giuseppe Migliara, Francesca Aloisi, Letizia Santinelli, Enrico Palermo, Luca Bortolani, Alessandro Lazzaro, Giancarlo Ceccarelli, Ombretta Turriziani, Claudio Maria Mastroianni, Guido Antonelli, Gabriella d'Ettorre, Carolina Scagnolari   +18 more
wiley   +1 more source

Darunavir-cobicistat versus lopinavir-ritonavir in the treatment of COVID-19 infection (DOLCI): A multicenter observational study.

PLoS ONE, 2022
BackgroundCoronavirus Disease 2019 (COVID-19) is an evolving pandemic that urged the need to investigate various antiviral therapies. This study was conducted to compare efficacy and safety outcomes of darunavir-cobicistat versus lopinavir-ritonavir in ...
Eman Zeyad I Elmekaty, Rim Alibrahim, Rania Hassanin, Sitelbanat Eltaib, Ahmed Elsayed, Fatima Rustom, Mohamed Izham Mohamed Ibrahim, Mohammed Abu Khattab, Hussam Al Soub, Muna Al Maslamani, Abdullatif Al-Khal   +10 more
doaj   +1 more source

Safety and Effectiveness of Glecaprevir/Pibrentasvir in Children and Adolescents With Chronic Hepatitis C: Reports From All‐Case Post‐Marketing Surveillance in Japan

Hepatology Research, Volume 56, Issue 8, Page 1202-1212, August 2026.
ABSTRACT Aim The aim of this all‐case post‐marketing study was to evaluate the real‐world safety and effectiveness in all children and adolescents with chronic hepatitis C with or without compensated cirrhosis treated with glecaprevir/pibrentasvir (G/P) in Japan. Methods This prospective, observational post‐marketing surveillance study was conducted at
Tatsuki Mizuochi, Katsuyoshi Kawana, Mariko Kobayashi, Eri Iwashita, Itaru Iwama, Daiki Abukawa, Hitoshi Tajiri   +6 more
wiley   +1 more source

Role of darunavir in the management of HIV infection

HIV/AIDS: Research and Palliative Care, 2009
R Monica Lascar, Paul BennThe Mortimer Market Centre, Camden PCT, London WC1E 6JBAbstract: There is an ongoing need for potent antiretroviral therapies to deal with the increasing pool of treatment-experienced patients with multiple drug resistance.
R Monica Lascar, Paul Benn
doaj  

Comparative efficacy of repurposed drugs lopinavir-ritonavir and darunavir-ritonavir in hospitalised COVID-19 patients: insights from a tertiary centre cohort

Frontiers in Cellular and Infection Microbiology
BackgroundDrug repurposing has become a widely adopted strategy to minimise research time, costs, and associated risks. Combinations of protease inhibitors such as lopinavir and darunavir with ritonavir have been repurposed as treatments for COVID-19 ...
Dóra Paróczai, Dóra Paróczai, András Bikov, András Bikov, Andreea Blidaru, Emanuel Bobu, Ana Lascu, Ana Lascu, Cristian Ion Mot, Cristian Ion Mot, Stefan Mihaicuta, Stefan Mihaicuta, Stefan Frent, Stefan Frent   +13 more
doaj   +1 more source

A novel ultra performance liquid chromatography-PDA method development and validation for darunavir in bulk and its application to marketed dosage form

Journal of Pharmacy and Bioallied Sciences, 2021
Aims and Objective: The aim of this study was to develop and validate a novel ultra-performance liquid chromatographic method for estimation of darunavir in a bulk and tablet dosage form. Materials and Methods: The chromatographic separation was achieved
Sabyasachi Biswal, Sumanta Mondal, Prasenjit Mondal   +2 more
doaj   +1 more source

Advancing Antiviral Design: Integrating Natural Products, Computation and Targeted Delivery

Chemical Biology &Drug Design, Volume 108, Issue 1, July 2026.
A stepwise translational framework linking natural‐product discovery, computational prioritisation, experimental validation, lead optimisation and targeted delivery is proposed to advance antiviral design. ABSTRACT The COVID‐19 pandemic highlighted the role of rapid viral mutation and global connectivity in accelerating viral emergence and spread ...
Adedayo Ayodeji Lanrewaju, Abimbola Motunrayo Folami, Saheed Sabiu, Feroz Mahomed Swalaha   +3 more
wiley   +1 more source